Former Altria Group executive Brian Quigley has been appointed as the new CEO of Respira Technologies. Mario Danek, the founder of Respira, will now serve as the Chief Technology Officer.
Respira is a health technology company supported by California venture capital. The company focuses on commercializing medical inhalation device technology to improve patient outcomes. Currently, the company is working with the FDA to achieve joint product authorization and launch the first inhalable prescription smoking cessation therapy.
Quigley spent 16 years working at Altria Group, serving as the President and CEO of the company's smokeless and innovative products/e-cigarette business for 7 years. He has also been an investor in the CBD and alcohol industries, and has served on the board of directors for Mustgrow Biologics and Belle Isle Craft Spirits.
Due to Respira's efforts to secure funding for clinical trials, Danek made significant changes to the company's leadership structure. With a successful business background and experience leading a Fortune 150 company, Quigley's appointment as CEO will help drive Respira into its next phase as it prepares to submit investigational new drug applications and begin human clinical trials. This shift will allow Danek to focus on Respira's technology, specifically inventing and improving its innovative inhalation device for multiple potential indications and target markets.
Statement
This article is compiled from third-party information and is only intended for industry exchange and learning.
This article does not represent the views of 2FIRSTS and 2FIRSTS is unable to confirm the authenticity and accuracy of the article's contents. The translation of this article is only intended for industry-related communication and research.
Due to limitations in the level of translation, the translated version of this article may not fully express the same meaning as the original. Please refer to the original article for accuracy.
In regards to any domestic issues, as well as those concerning Hong Kong, Macau, Taiwan, and foreign affairs, 2FIRSTS maintains complete alignment with the Chinese government.
The copyright of compiled information belongs to the original media and authors. If there is any infringement, please contact us to have it removed.
Disclaimer
This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.
Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.
The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.
This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.
Copyright Notice
This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.
No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.
For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.
AI-Assisted Translation and Editing Notice
Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.
Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.
